Peripheral Vascular Anomalies, Malformations, and Vascular Tumors

Vascular Medicine: A Companion to Braunwald's Heart Disease: Second Edition

Volumn , Issue , 2013, Pages 790-809

  Blei, Francine ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881240207     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2930-6.00064-1     Document Type: Chapter

References (184)

1. Mulliken J.B., Glowacki J. Classification of pediatric vascular lesions. Plast Reconstr Surg 1982, 70(1):120-121.
2. Yu Y., Fuhr J., Boye E., et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells 2006, 24(6):1605-1612.
3. Mulliken J.B., Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 2004, 50(6):875-882.
4. Konez O., Burrows P.E., Mulliken J.B., et al. Angiographic features of rapidly involuting congenital hemangioma (RICH). Pediatr Radiol 2003, 33(1):15-19.
5. Baselga E., Cordisco M.R., Garzon M., et al. Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy: a case series. Br J Dermatol 2008, 158(6):1363-1370.
6. North P.E., Waner M., James C.A., et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol 2001, 137(12):1607-1620.
7. Enjolras O., Mulliken J.B., Boon L.M., et al. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg 2001, 107(7):1647-1654.
8. Suh K.Y., Frieden I.J. Infantile hemangiomas with minimal or arrested growth: a retrospective case series. Arch Dermatol 2010, 146(9):971-976.
9. Haggstrom A.N., Drolet B.A., Baselga E., et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007, 150(3):291-294.
10. Burton B.K., Schulz C.J., Angle B., et al. An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn 1995, 15(3):209-214.
11. Bauland C.G., Smit J.M., Bartelink L.R., et al. Hemangioma in the newborn: increased incidence after chorionic villus sampling. Prenat Diagn 2010, 30(10):913-917.
12. Lopez Gutierrez J.C., Avila L.F., Sosa G., et al. Placental anomalies in children with infantile hemangioma. Pediatr Dermatol 2007, 24(4):353-355.
13. Colonna V., Resta L., Napoli A., et al. Placental hypoxia and neonatal haemangioma: clinical and histological observations. Br J Dermatol 2010, 162(1):208-209.
14. Waner M., North P.E., Scherer K.A., et al. The nonrandom distribution of facial hemangiomas. Arch Dermatol 2003, 139(7):869-875.
15. Haggstrom A.N., Lammer E.J., Schneider R.A., et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006, 117(3):698-703.
16. Haggstrom A.N., Drolet B.A., Baselga E., et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006, 118(3):882-887.
17. Metry D.W., Hawrot A., Altman C., et al. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol 2004, 140(5):591-596.
18. Metry D.W. Potential complications of segmental hemangiomas of infancy. Semin Cutan Med Surg 2004, 23(2):107-115.
19. Stockman A., Boralevi F., Taieb A., et al. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 2007, 214(1):40-45.
20. Drolet B., Garzon M. SACRAL syndrome. Dermatology 2007, 215(4):360. author reply -1.
21. Metry D.W., Haggstrom A.N., Drolet B.A., et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet A 2006, 140(9):975-986.
22. Haggstrom A.N., Garzon M.C., Baselga E., et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics 2010, 126(2):e418-e426.
23. Oza V.S., Wang E., Berenstein A., et al. PHACES association: a neuroradiologic review of 17 patients. AJNR Am J Neuroradiol 2008, 29(4):807-813.
24. Heyer G.L., Dowling M.M., Licht D.J., et al. The cerebral vasculopathy of PHACES syndrome. Stroke 2008, 39(2):308-316.
25. Kasabach H., Merritt K. Capillary hemangioma with extensive purpura. Am J Dis Child 1940, 59:1063.
26. Sarkar M., Mulliken J.B., Kozakewich H.P., et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997, 100(6):1377-1386.
27. Enjolras O., Wassef M., Mazoyer E., et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 1997, 130(4):631-640.
28. Gruman A., Liang M.G., Mulliken J.B., et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol 2005, 52(4):616-622.
29. Blatt J., Stavas J., Moats-Staats B., et al. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010, 55(7):1396-1398.
30. Chu C.Y., Hsiao C.H., Chiu H.C. Transformation between kaposiform hemangioendothelioma and tufted angioma. Dermatology 2003, 206(4):334-337.
31. Gilmore A., Kelsberg G., Safranek S. Clinical inquiries. What's the best treatment for pyogenic granuloma. J Fam Pract 2010, 59(1):40-42.
32. Greene W., Kuhne K., Ye F., et al. Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res 2007, 133:69-127. PMCID: 2798888.
33. Patrikidou A., Vahtsevanos K., Charalambidou M., et al. Non-AIDS Kaposi's sarcoma in the head and neck area. Head Neck 2009, 31(2):260-268.
34. Barbaro G., Barbarini G. HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep 2007, 17(5):1121-1126.
35. Rosen S., Smoller B.R. Port-wine stains: a new hypothesis. J Am Acad Dermatol 1987, 17(1):164-166.
36. Smoller B.R., Rosen S. Port-wine stains. A disease of altered neural modulation of blood vessels?. Arch Dermatol 1986, 122(2):177-179.
37. Chang C.J., Yu J.S., Nelson J.S. Confocal microscopy study of neurovascular distribution in facial port wine stains (capillary malformation). J Formos Med Assoc 2008, 107(7):559-566.
38. Blei F. Congenital lymphatic malformations. Ann N Y Acad Sci 2008, 1131:185-194.
39. Mazoyer E., Enjolras O., Bisdorff A., et al. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol 2008, 144(7):861-867.
40. Tan W.H., Baris H.N., Burrows P.E., et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007, 44(9):594-602. PMCID: 2597949.
41. Bisdorff A., Mulliken J.B., Carrico J., et al. Intracranial vascular anomalies in patients with periorbital lymphatic and lymphaticovenous malformations. AJNR Am J Neuroradiol 2007, 28(2):335-341.
42. Viswanathan V., Smith E.R., Mulliken J.B., et al. Infantile hemangiomas involving the neuraxis: clinical and imaging findings. AJNR Am J Neuroradiol 2009, 30(5):1005-1013.
43. Hess C.P., Fullerton H.J., Metry D.W., et al. Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome. AJNR Am J Neuroradiol 2010, 31(10):1980-1986.
44. Thiex R., Mulliken J.B., Revencu N., et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. AJNR Am J Neuroradiol 2010, 31(4):775-779.
45. Pascual-Castroviejo I., Alvarez-Linera J., Coya J., et al. Pascual-Castroviejo type II syndrome (P-CIIS). Importance of the presence of persistent embryonic arteries. Childs Nerv Syst 2011, 27(4):617-625.
46. Metry D.W., Garzon M.C., Drolet B.A., et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol 2009, 26(4):381-398.
47. Hobert J.A., Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009, 11(10):687-694.
48. Blumenthal G.M., Dennis P.A. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008, 16(11):1289-1300.
49. Elia D., Garel C., Enjolras O., et al. Prenatal imaging findings in rapidly involuting congenital hemangioma of the skull. Ultrasound Obstet Gynecol 2008, 31(5):572-575.
50. Morris J., Abbott J., Burrows P., et al. Antenatal diagnosis of fetal hepatic hemangioma treated with maternal corticosteroids. Obstet Gynecol 1999, 94(5 Pt 2):813-815.
51. Schmitz R., Heinig J., Klockenbusch W., et al. Antenatal diagnosis of a giant fetal hepatic hemangioma and treatment with maternal corticosteroid. Ultraschall Med 2009, 30(3):223-226.
52. Arbiser J.L., Bonner M.Y., Berrios R.L. Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis. Curr Mol Med 2009, 9(8):929-934.
53. Bischoff J. Progenitor cells in infantile hemangioma. J Craniofac Surg 2009, 20(Suppl 1):695-697. PMCID: 2810465.
54. Boye E., Olsen B.R. Signaling mechanisms in infantile hemangioma. Curr Opin Hematol 2009, 16(3):202-208. PMCID: 2895461.
55. Jinnin M., Ishihara T., Boye E., et al. Recent progress in studies of infantile hemangioma. J Dermatol 2010, 37(4):283-298.
56. Itinteang T., Tan S.T., Brasch H., et al. Primitive mesodermal cells with a neural crest stem cell phenotype predominate proliferating infantile haemangioma. J Clin Pathol 2010, 63(9):771-776.
57. Dadras S.S., North P.E., Bertoncini J., et al. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol 2004, 17(9):1068-1079.
58. Nguyen V.A., Kutzner H., Furhapter C., et al. Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. Mod Pathol 2006, 19(2):291-298.
59. Khan Z.A., Boscolo E., Picard A., et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008, 118(7):2592-2599. PMCID: 2413184.
60. Itinteang T., Tan S.T., Brasch H., et al. Haemogenic endothelium in infantile haemangioma. J Clin Pathol 2010, 63(11):982-986.
61. Perry B.N., Govindarajan B., Bhandarkar S.S., et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 2006, 126(10):2316-2322.
62. Boye E., Yu Y., Paranya G., et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001, 107(6):745-752. PMCID: 208946.
63. Walter J.W., North P.E., Waner M., et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002, 33(3):295-303.
64. Yu Y., Flint A.F., Mulliken J.B., et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004, 103(4):1373-1375.
65. Khan Z.A., Melero-Martin J.M., Wu X., et al. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 2006, 108(3):915-921. PMCID: 1895853.
66. Kleinman M.E., Blei F., Gurtner G.C. Circulating endothelial progenitor cells and vascular anomalies. Lymphat Res Biol 2005, 3(4):234-239.
67. North P.E., Waner M., Mizeracki A., et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001, 137(5):559-570.
68. Mihm M.C., Nelson J.S. Hypothesis: the metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol 2010, 37:83-87.
69. Greenberger S., Adini I., Boscolo E., et al. Targeting NF-kappaB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010, 13(4):327-335.
70. Greenberger S., Boscolo E., Adini I., et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010, 362(11):1005-1013. PMCID: 2845924.
71. Sun Z.J., Zhao Y.F., Zhang W.F. Immune response: a possible role in the pathophysiology of hemangioma. Med Hypotheses 2007, 68(2):353-355.
72. Jinnin M., Medici D., Park L., et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008, 14(11):1236-1246. PMCID: 2593632.
73. Brooks B.P., Dagenais S.L., Nelson C.C., et al. Mutation of the FOXC2 gene in familial distichiasis. J AAPOS 2003, 7(5):354-357.
74. Levinson K.L., Feingold E., Ferrell R.E., et al. Age of onset in hereditary lymphedema. J Pediatr 2003, 142(6):704-708.
75. Eerola I., Boon L.M., Mulliken J.B., et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003, 73(6):1240-1249. PMCID: 1180390.
76. Boon L.M., Mulliken J.B., Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 2005, 15(3):265-269.
77. Wouters V., Limaye N., Uebelhoer M., et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010, 18(4):414-420. PMCID: 2841708.
78. Hershkovitz D., Bercovich D., Sprecher E., et al. RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations. Br J Dermatol 2008, 158(5):1035-1040.
79. Hershkovitz D., Bergman R., Sprecher E. A novel mutation in RASA1 causes capillary malformation and limb enlargement. Arch Dermatol Res 2008, 300(7):385-388.
80. Comi A.M. Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol 2007, 5(4):257-264.
81. Orlow S.J., Isakoff M.S., Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr 1997, 131(4):643-646.
82. Balakrishnan K., Perkins J.A. Management of airway hemangiomas. Expert Rev Respir Med 2010, 4(4):455-462.
83. Schwartz S.R., Blei F., Ceisler E., et al. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. J AAPOS 2006, 10(3):262-268.
84. Schwartz S.R., Kodsi S.R., Blei F., et al. Treatment of capillary hemangiomas causing refractive and occlusional amblyopia. J AAPOS 2007, 11(6):577-583.
85. Al-Mahdi H. Iris depigmentation: an unusual complication of intralesional corticosteroid injection for capillary hemangioma. Middle East Afr J Ophthalmol 2010, 17(1):100-102. PMCID: 2880367.
86. Maguiness S.M., Frieden I.J. Current management of infantile hemangiomas. Semin Cutan Med Surg 2010, 29(2):106-114.
87. Huang S.A., Tu H.M., Harney J.W., et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000, 343(3):185-189.
88. Christison-Lagay E.R., Burrows P.E., Alomari A., et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 2007, 42(1):62-67. discussion 7-8.
89. Chamlin S.L., Haggstrom A.N., Drolet B.A., et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007, 151(6):684-689. 9 e1.
90. Ho N.T., Lansang P., Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 2007, 56(1):63-68.
91. McCuaig C.C., Dubois J., Powell J., et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 2009, 26(2):203-212.
92. Sugarman J.L., Mauro T.M., Frieden I.J. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002, 138(3):314-316.
93. Metz B.J., Rubenstein M.C., Levy M.L., et al. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004, 140(7):867-870.
94. Lapidoth M., Ben-Amitai D., Bhandarkar S., et al. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol 2009, 60(2):350-351.
95. Faughnan M.E., Palda V.A., Garcia-Tsao G., et al. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet 2011, 48(2):73-87.
96. Scher D.M. Orthopedic issues in patients with vascular anomalies. Lymphat Res Biol 2004, 2(1):51-55.
97. Rebarber A., Roman A.S., Roshan D., et al. Obstetric management of Klippel-Trenaunay syndrome. Obstet Gynecol 2004, 104(5 Pt 2):1205-1208.
98. Cohen S.G. Hemangiomas in infancy and childhood: psychosocial issues require close attention. Adv Nurse Pract 2005, 13(11):41-44.
99. Lande R.G., Crawford P.M., Ramsey B.J. Psychosocial impact of vascular birthmarks. Facial Plast Surg Clin North Am 2001, 9(4):561-567.
100. Tanner J.L., Dechert M.P., Frieden I.J. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998, 101(3 Pt 1):446-452.
101. Oster H. Emotion in the infant's face: insights from the study of infants with facial anomalies. Ann N Y Acad Sci 2003, 1000:197-204.
102. Williams E.F., Hochman M., Rodgers B.J., et al. A psychological profile of children with hemangiomas and their families. Arch Facial Plast Surg 2003, 5(3):229-234.
103. Ridner S.H. The psycho-social impact of lymphedema. Lymphat Res Biol 2009, 7(2):109-112. PMCID: 2904185.
104. Cabo H., Cohen E.S., Casas G.J., et al. Cutaneous angiosarcoma arising on the radiation site of a congenital facial hemangioma. Int J Dermatol 1998, 37(8):638-639.
105. Haddy N., Andriamboavonjy T., Paoletti C., et al. Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. Radiother Oncol 2009, 93(2):377-382.
106. Haddy N., Dondon M.G., Paoletti C., et al. Breast cancer following radiotherapy for a hemangioma during childhood. Cancer Causes Control 2010, 21(11):1807-1816.
107. Sovinz P., Urban C., Hausegger K. Life-threatening hemangiomatosis of the liver in an infant: multimodal therapy including cyclophosphamide and secondary acute myeloid leukemia. Pediatr Blood Cancer 2006, 47(7):972-973.
108. Al Dhaybi R., Agoumi M., Powell J., et al. Lymphangiosarcoma complicating extensive congenital mixed vascular malformations. Lymphat Res Biol 2010, 8(3):175-179.
109. Al-Mubarak L., Al-Khenaizan S. A wolf in sheep's disguise: rhabdomyosarcoma misdiagnosed as infantile hemangioma. J Cutan Med Surg 2009, 13(5):276-279.
110. Assen Y.J., Madern G.C., de Laat P.C., et al. Rhabdoid tumor mimicking hemangioma. Pediatr Dermatol 2011, 28(3):295-298.
111. Boon L.M., Fishman S.J., Lund D.P., et al. Congenital fibrosarcoma masquerading as congenital hemangioma: report of two cases. J Pediatr Surg 1995, 30(9):1378-1381.
112. Hassanein A., Fishman S., Mulliken J., et al. Metastatic neuroblastoma mimicking infantile hemangioma. J Pediatr Surg 2010, 45(10):2045-2049.
113. Hayward P.G., Orgill D.P., Mulliken J.B., et al. Congenital fibrosarcoma masquerading as lymphatic malformation: report of two cases. J Pediatr Surg 1995, 30(1):84-88.
114. Martinez-Perez D., Fein N.A., Boon L.M., et al. Not all hemangiomas look like strawberries: uncommon presentations of the most common tumor of infancy. Pediatr Dermatol 1995, 12(1):1-6.
115. Megarbane H., Doz F., Manach Y., et al. Neonatal rhabdomyosarcoma misdiagnosed as a congenital hemangioma. Pediatr Dermatol 2011, 28(3):299-301.
116. Requena C., Miranda L., Canete A., et al. Congenital fibrosarcoma simulating congenital hemangioma. Pediatr Dermatol 2008, 25(1):141-144.
117. Yan A.C., Chamlin S.L., Liang M.G., et al. Congenital infantile fibrosarcoma: a masquerader of ulcerated hemangioma. Pediatr Dermatol 2006, 23(4):330-334.
118. Nord K.M., Kandel J., Lefkowitch J.H., et al. Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics 2006, 118(3):e907-e913.
119. Rossi S., Fletcher C.D. Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am J Surg Pathol 2002, 26(10):1319-1329.
120. Buckmiller L., Richter G., Suen J. Diagnosis and management of hemangiomas and vascular malformations of the head and neck. Oral Dis 2010, 16(5):405-418.
121. Stier M.F., Glick S.A., Hirsch R.J. Laser treatment of pediatric vascular lesions: port wine stains and hemangiomas. J Am Acad Dermatol 2008, 58(2):261-285.
122. Rizzo C., Brightman L., Chapas A.M., et al. Outcomes of childhood hemangiomas treated with the pulsed-dye laser with dynamic cooling: a retrospective chart analysis. Dermatol Surg 2009, 35(12):1947-1954.
123. Hunzeker C.M., Geronemus R.G. Treatment of superficial infantile hemangiomas of the eyelid using the 595-nm pulsed dye laser. Dermatol Surg 2010, 36(5):590-597.
124. Li D.N., Gold M.H., Sun Z.S., et al. Treatment of infantile hemangioma with optimal pulse technology. J Cosmet Laser Ther 2010, 12(3):145-150.
125. Frieden I.J. Commentary: early laser treatment of periorbital infantile hemangiomas may work, but is it really the best treatment option?. Dermatol Surg 2010, 36(5):598-601.
126. Greene A.K. Corticosteroid treatment for problematic infantile hemangioma: evidence does not support an increased risk for cerebral palsy. Pediatrics 2008, 121(6):1251-1252.
127. Greene A.K. Systemic corticosteroid is effective and safe treatment for problematic infantile hemangioma. Pediatr Dermatol 2010, 27(3):322-323.
128. Ray W.Z., Lee A., Blackburn S.L., et al. Pseudotumor cerebri following tapered corticosteroid treatment in an 8-month-old infant. J Neurosurg Pediatr 2008, 1(1):88-90.
129. Maronn M.L., Corden T., Drolet B.A. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol 2007, 143(9):1224-1225.
130. Aviles R., Boyce T.G., Thompson D.M. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc 2004, 79(2):243-245.
131. Deboer M.D., Boston B.A. Failure-to-thrive in an infant following injection of capillary hemangioma with triamcinolone acetonide. Clin Pediatr (Phila) 2008, 47(3):296-299.
132. Goyal R., Watts P., Lane C.M., et al. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology 2004, 111(2):389-395.
133. Kushner B.J., Lemke B.N. Bilateral retinal embolization associated with intralesional corticosteroid injection for capillary hemangioma of infancy. J Pediatr Ophthalmol Strabismus 1993, 30(6):397-399.
134. Ang L.P., Lee M.W., Seah L.L., et al. Orbital cellulitis following intralesional corticosteroid injection for periocular capillary haemangioma. Eye 2007, 21(7):999-1001.
135. Buckmiller L.M., Francis C.L., Glade R.S. Intralesional steroid injection for proliferative parotid hemangiomas. Int J Pediatr Otorhinolaryngol 2008, 72(1):81-87.
136. Leaute-Labreze C., Dumas de la Roque E., Hubiche T., et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008, 358(24):2649-2651.
137. Leboulanger N., Fayoux P., Teissier N., et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010, 74(11):1254-1257.
138. Haider K.M., Plager D.A., Neely D.E., et al. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS 2010, 14(3):251-256.
139. Rosbe K.W., Suh K.Y., Meyer A.K., et al. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg 2010, 136(7):658-665.
140. Tan S.T., Itinteang T., Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 2011, 64(2929).
141. Mazereeuw-Hautier J., Hoeger P.H., Benlahrech S., et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010, 157(2):340-342.
142. Pope E., Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010, 146(5):564-565.
143. Guo S., Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010, 128(2):255-256.
144. Bonifazi E., Acquafredda A., Milano A., et al. Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol 2010, 27(2):195-196.
145. Breur J.M., de Graaf M., Breugem C.C., et al. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol 2011, 28(2):169-171.
146. Holland K.E., Frieden I.J., Frommelt P.C., et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010, 146(7):775-778.
147. Allford M.A., Brown J.L. Case report: intraoperative hypoglycaemia in a child treated with propranolol following a short preoperative fast. Eur J Anaesthesiol 2011, 28(1):71-72.
148. Lamy S., Lachambre M.P., Lord-Dufour S., et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010, 53(5-6):200-208.
149. Itinteang T., Brasch H.D., Tan S.T., et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg 2011, 64(6):759-765.
150. Sans V., de la Roque E.D., Berge J., et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009, 124(3):e423-e431.
151. Storch C.H., Hoeger P.H. Propranolol for infantile haemangiomas-insights into the molecular mechanisms of action. Br J Dermatol 2010, 163(2):269-274.
152. Naouri M., Schill T., Maruani A., et al. Successful treatment of ulcerated haemangioma with propranolol. J Eur Acad Dermatol Venereol 2010, 24(9):1109-1112.
153. Barlow C.F., Priebe C.J., Mulliken J.B., et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998, 132(3 Pt 1):527-530.
154. Michaud A.P., Bauman N.M., Burke D.K., et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004, 114(7):1231-1236.
155. Chao Y.H., Liang D.C., Chen S.H., et al. Interferon-alpha for alarming hemangiomas in infants: experience of a single institution. Pediatr Int 2009, 51(4):469-473.
156. Perez-Valle S., Peinador M., Herraiz P., et al. Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis. Acta Paediatr 2010, 99(2):311-315.
157. Lazaridou E., Giannopoulou C., Apalla Z., et al. Calcineurin inhibitors in the treatment of cutaneous infantile haemangiomas. J Eur Acad Dermatol Venereol 2010, 24(5):614-615.
158. Yao Y.G., Duh E.J. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?. Biochem Biophys Res Commun 2004, 321(3):648-656.
159. Gollogly L.K., Ryeom S.W., Yoon S.S. Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis. J Surg Res 2007, 142(1):129-136. PMCID: 1995402.
160. Serena T. Wound closure and gradual involution of an infantile hemangioma using a noncontact, low-frequency ultrasound therapy. Ostomy Wound Manage 2008, 54(2):68-71.
161. Spector J.A., Blei F., Zide B.M. Early surgical intervention for proliferating hemangiomas of the scalp: indications and outcomes. Plast Reconstr Surg 2008, 122(2):457-462.
162. Waner M., Kastenbaum J., Scherer K. Hemangiomas of the nose: surgical management using a modified subunit approach. Arch Facial Plast Surg 2008, 10(5):329-334.
163. Warren S.M., Longaker M.T., Zide B.M. The subunit approach to nasal tip hemangiomas. Plast Reconstr Surg 2002, 109(1):25-30.
164. Watanabe S., Takagi S., Sato Y., et al. Early surgical intervention for Japanese children with infantile hemangioma of the craniofacial region. J Craniofac Surg 2009, 20(Suppl 1):707-709.
165. Wu J.K., Rohde C.H. Purse-string closure of hemangiomas: early results of a follow-up study. Ann Plast Surg 2009, 62(5):581-585.
166. Zide B.M., Glat P.M., Stile F.L., et al. Vascular lip enlargement: part I. Hemangiomas--tenets of therapy. Plast Reconstr Surg 1997, 100(7):1664-1673.
167. Canavese F., Soo B.C., Chia S.K., et al. Surgical outcome in patients treated for hemangioma during infancy, childhood, and adolescence: a retrospective review of 44 consecutive patients. J Pediatr Orthop 2008, 28(3):381-386.
168. Levi M., Schwartz S., Blei F., et al. Surgical treatment of capillary hemangiomas causing amblyopia. J AAPOS 2007, 11(3):230-234.
169. Mandrekas A.D., Zambacos G.J., Hapsas D.A. Pediatric nasal reconstruction for nasal tip hemangioma. Plast Reconstr Surg 2010, 125(5):1571-1572. author reply 3.
170. Mehta M., Waner M., Fay A. Amniotic membrane grafting in the management of conjunctival vascular malformations. Ophthal Plast Reconstr Surg 2009, 25(5):371-375.
171. Mulliken J.B., Rogers G.F., Marler J.J. Circular excision of hemangioma and purse-string closure: the smallest possible scar. Plast Reconstr Surg 2002, 109(5):1544-1554. discussion 55.
172. Burrows P.E., Mulliken J.B., Fishman S.J., et al. Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child. J Craniofac Surg 2009, 20(Suppl 1):597-602.
173. Niramis R., Watanatittan S., Rattanasuwan T. Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients. Eur J Pediatr Surg 2010, 20(3):178-182.
174. Smith M.C., Zimmerman M.B., Burke D.K., et al. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 2009, 119(1):107-115.
175. Narkio-Makela M., Makela T., Saarinen P., et al. Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response. Eur Arch Otorhinolaryngol 2011, 268:123-1219.
176. Greene A.K., Burrows P.E., Smith L., et al. Periorbital lymphatic malformation: clinical course and management in 42 patients. Plast Reconstr Surg 2005, 115(1):22-30.
177. Oliver G., Srinivasan R.S. Lymphatic vasculature development: current concepts. Ann N Y Acad Sci 2008, 1131:75-81.
178. Oliver G., Srinivasan R.S. Endothelial cell plasticity: how to become and remain a lymphatic endothelial cell. Development 2010, 137(3):363-372. PMCID: 2858906.
179. Perkins J.A., Manning S.C., Tempero R.M., et al. Lymphatic malformations: review of current treatment. Otolaryngol Head Neck Surg 2010, 142(6):795-803. e1.
180. Perkins J.A., Manning S.C., Tempero R.M., et al. Lymphatic malformations: current cellular and clinical investigations. Otolaryngol Head Neck Surg 2010, 142(6):789-794.
181. Rockson S.G. Current concepts and future directions in the diagnosis and management of lymphatic vascular disease. Vasc Med 2010, 15(3):223-231.
182. Mayrovitz H.N. The standard of care for lymphedema: current concepts and physiological considerations. Lymphat Res Biol 2009, 7(2):101-108.
183. Brorson H. From lymph to fat: complete reduction of lymphoedema. Phlebology 2010, 25(Suppl 1):52-63.
184. Rockson S.G. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol 2008, 52(10):799-806.